Nonsquamous Disease

CHICAGO — Including liquid biopsy in the initial diagnostic workup of patients with stage IV nonsquamous non-small cell lung cancer resulted in a quicker initiation of first-line therapy and a higher detection rate of actionable mutations.

The combination of atezolizumab, carboplatin and pemetrexed demonstrated encouraging activity among patients with nonsquamous non-small cell lung cancer and untreated, asymptomatic brain metastases, according to phase 2 study results.